Search results for " type 2"

showing 10 items of 761 documents

AZITHROMYCIN IN AN OLDER WOMAN WITH DIABETIC GASTROPARESIS

2008

Diabetic neuropathy is a common chronic complication of diabetes and cause of significant morbidity and mortality, because it may involve the autonomous and peripheral nervous systems. Autonomic diabetic neuropathy is a challenging chronic complication of long-standing diabetes manifested with hypotension, syncope, gastroparesis, diarrhea, constipation, bladder dysfunction, sexual dysfunction, cardiac arrest, and/or sudden death. We present a case of diabetic gastroparesis in an older woman. The patient was an 83-year-old woman with a 40-year history of type 2 diabetes who was admitted with hypoglycemia, malnutrition, persistent vomiting, and obstinate constipation. After several unsuccessf…

Pediatricsmedicine.medical_specialtyDiabetic neuropathyGastroparesisType 2 diabetesHypoglycemiaAzithromycinAzithromycinSudden deathDiabetes mellitusMedicineHumansPharmacology (medical)GastroparesisInfusions IntravenousPharmacologyAged 80 and overbusiness.industryGeneral Medicinemedicine.diseaseSurgeryAnti-Bacterial AgentsDiabetes Mellitus Type 2VomitingFemalemedicine.symptombusinessmedicine.drug
researchProduct

A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents

2010

BACKGROUND AND PURPOSE Cannabinoid CB1 receptor antagonists reduce food intake and body weight, but clinical use in humans is limited by effects on the CNS. We have evaluated a novel cannabinoid antagonist (AM6545) designed to have limited CNS penetration, to see if it would inhibit food intake in rodents, without aversive effects. EXPERIMENTAL APPROACH Cannabinoid receptor binding studies, cAMP assays, brain penetration studies and gastrointestinal motility studies were carried out to assess the activity profile of AM6545. The potential for AM6545 to induce malaise in rats and the actions of AM6545 on food intake and body weight were also investigated. KEY RESULTS AM6545 binds to CB1 recep…

PharmacologyAM251medicine.medical_specialtyCannabinoid receptormedicine.medical_treatmentAntagonistPharmacologyBiologyEndocrinologyInternal medicinemedicineCannabinoid receptor bindingCannabinoid receptor type 2Cannabinoid receptor antagonistlipids (amino acids peptides and proteins)CannabinoidReceptormedicine.drugBritish Journal of Pharmacology
researchProduct

Vitamin D in the Prevention and Treatment of Diabetic Neuropathy.

2022

Neuropathy is one of the most important complications of diabetes. According to recent advances, vitamin D deficiency might play a role in the development and progression of diabetic neuropathy. Moreover, therapeutic vitamin D supplementation has the potential to improve this condition. The aim of the present review was to summarize new data available in this area.The PubMed database was searched for articles written in English and published through September 2021, using combinations of the following key words: vitamin D, diabetes, diabetes mellitus, diabetic neuropathy, polyneuropathy, peripheral neuropathy, cardiac autonomic neuropathy, supplementation, and therapy.A number of studies hav…

PharmacologyDiabetes Mellitus Type 2Diabetic NeuropathiesHumansPharmacology (medical)cardiovascular autonomic neuropathy sensory neuropathy vitamin DVitaminsVitamin DVitamin D DeficiencyClinical therapeutics
researchProduct

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction

2022

The incretin pathway is a self-regulating feedback system connecting the gut with the brain, pancreas, and liver. Its predominant action is on the postprandial glucose levels, with extraglycemic effects on fat metabolism and endovascular function. Of the two main incretin hormones released with food ingestion, the actions of glucagon-like peptide-1 (GLP-1) have been exploited for therapeutic benefit. However, little attention has been paid to glucose-dependent insulinotropic polypeptide (GIP) until the recent experimental introduction of dual agonists, or "twincretins". Interestingly, simultaneous activation of both receptors is not only replicative of normal physiology, it seems to be an i…

PharmacologyInternal Medicineglucagon-like peptide-1 glucose-dependent insulinotropic polypeptide incretins type 2 diabetesDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy
researchProduct

Statins and new-onset diabetes

2013

Statins are highly efficacious lipid modifying agents that reduce the risk for cardiovascular (CV) events in both primary and secondary prevention settings. However, statins affect molecular mechanisms which adversely impact on insulin sensitivity and β-cell function, thereby increasing risk for new onset diabetes mellitus (NOD). Defining the mechanisms involved is the focus of considerable current investigation. The statins reduce the risk for CV events in normoglycemic patients as well as in those with diabetes mellitus (DM) and their benefits outweigh the risk of inducing NOD. We review the clinical evidence for NOD with statin treatment, as well as the potential mechanisms involved. Our…

PharmacologySecondary preventionLIPID MODIFYING AGENTSbusiness.industrynutritional and metabolic diseasesInsulin sensitivityNodPharmacologyStatin treatmentBioinformaticsmedicine.diseaseRisk AssessmentPrimary PreventionDiabetes Mellitus Type 2New onset diabetesCardiovascular DiseasesDiabetes mellitusDrug DiscoverySecondary PreventionmedicineHumansHydroxymethylglutaryl-CoA Reductase InhibitorsRisk assessmentbusinessnew-onset diabetes mellitus statin cardiovascular events insulin sensitivity primary prevention secondary prevention
researchProduct

Activin A and bone metastasis

2010

Activin A, is a multifunctional cytokine of the transforming growth factor-b superfamily of growth factors. This molecule has been shown to be implicated in the regulation of a broad range of important biological functions including bone remodelling. Therefore, a deregulation in the activin signalling pathway may result in disturbances of normal bone metabolism and, eventually, in the onset of severe pathological conditions associated with an altered bone resorption. These observations support the concept that Act A might also be implicated in the pathogenesis of bone metastasis. This review provides insight into the most recent advances in understanding the role of this growth factor in th…

PhysiologyGrowth factormedicine.medical_treatmentClinical BiochemistryBone metastasisBone NeoplasmsCell BiologyBiologymedicine.diseaseHedgehog signaling pathwayBone resorptionBone remodelingActivinsActivin bone metastasisPathogenesisGene Expression Regulation NeoplasticCytokineImmunologymedicineCancer researchAnimalsBone RemodelingActivin type 2 receptorsSignal Transduction
researchProduct

Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and disfunction: A potential rescue strategy

2021

Background: Ponatinib (PON), a third-generation tyrosine kinase inhibitor (TKI), has proven cardiovascular toxicity, with no known preventing agents usable to limit such side effect. Sodium-glucose cotransporter type 2 (SGLT2) inhibitors are a new class of glucose-lowering agents, featuring favorable cardiac and vascular effects. Aims: We assessed the effects of the SGLT2 inhibitors empagliflozin (EMPA) and dapagliflozin (DAPA) on human aortic endothelial cells (HAECs) and underlying vasculo-protective mechanisms in an in vitro model of PON-induced endothelial toxicity. Methods and results: We exposed HAECs to PON or vehicle (DMSO) in the presence or absence of EMPA (100 and 500 nmol/L) or …

Physiologymedicine.drug_classCellPharmacologyAutophagy; Ponatinib; Sodium-glucose cotransporter type 2 (SGLT2) inhibitors; Tyrosine kinase inhibitors; Vascular toxicityTyrosine-kinase inhibitorFlow cytometrychemistry.chemical_compoundmedicineAutophagyHumansViability assayDapagliflozinCellular SenescencePharmacologyTyrosine kinase inhibitorsMatrigelmedicine.diagnostic_testChemistrySodiumImidazolesEndothelial CellsEndothelial stem cellPyridazinesmedicine.anatomical_structureGlucoseDiabetes Mellitus Type 2Sodium-glucose cotransporter type 2 (SGLT2) inhibitorsToxicityPonatinibMolecular MedicineVascular toxicity
researchProduct

Prevention, diagnosis, and treatment of obesity. 2016 position statement of the Spanish Society for the Study of Obesity.

2017

Position statementAdultMaleSpanish Society for the Study of ObesityPALABRASPediatricsmedicine.medical_specialtyPediatric ObesityMEDLINEBariatric SurgeryComorbidity030204 cardiovascular system & hematologyModels BiologicalComorbidities03 medical and health sciencesDisease susceptibility0302 clinical medicineSleep Apnea SyndromesDiabetes mellitusDiagnosismedicinePrevalenceHumans030212 general & internal medicineObesityChildExerciseAdiposityDyslipidemiasInflammationbusiness.industryPreventionmedicine.diseaseObesityComorbidityDietTreatmentDiabetes Mellitus Type 2Cardiovascular DiseasesSpainBody CompositionFemaleAnti-Obesity AgentsDisease SusceptibilitybusinessEnergy IntakeEndocrinologia, diabetes y nutricion
researchProduct

Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights

2020

The current coronavirus disease 2019 (COVID-19) pandemic has led the scientific community to breach new frontiers in the understanding of human physiology and disease pathogenesis. It has been hypothesized that the human dipeptidyl peptidase 4 (DPP4) enzyme receptor may be a functional target for the spike proteins of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Since DPP4-inhibitors are currently used for the treatment of patients with type-2 diabetes (T2DM), there is currently high interest in the possibility that these agents, or incretin-based therapies (IBTs) in general, may be of benefit against the new coronavirus infection. Diabetes is associated with increased COV…

Prognostic variableCoronavirus disease 2019 (COVID-19)Pneumonia ViralIncretin030209 endocrinology & metabolism030204 cardiovascular system & hematologymedicine.disease_causeBioinformaticsIncretinsSeverity of Illness IndexGlucagon-Like Peptide-1 ReceptorBetacoronavirus03 medical and health sciences0302 clinical medicineDiabetes mellitusPandemicSeverity of illnessHumansHypoglycemic AgentsMedicinePharmacology (medical)PandemicsDipeptidyl peptidase-4CoronavirusPharmacologyDipeptidyl-Peptidase IV InhibitorsSARS-CoV-2business.industryCOVID-19medicine.diseaseDiabetes Mellitus Type 2Inflammation MediatorsCoronavirus InfectionsCardiology and Cardiovascular Medicinebusinessdiabetes DPP4 GLP1 incretins Betacoronavirus COVID-19 Coronavirus Infections Diabetes Mellitus Type 2 Dipeptidyl-Peptidase IV Inhibitors Glucagon-Like Peptide-1 Receptor Humans Hypoglycemic Agents Incretins Inflammation Mediators Pandemics Pneumonia Viral SARS-CoV-2 Severity of Illness Index
researchProduct

Mild obstructive sleep apnea increases hypertension risk, challenging traditional severity classification

2020

STUDY OBJECTIVES: The association of mild obstructive sleep apnea (OSA) with important clinical outcomes remains unclear. We aimed to investigate the association between mild OSA and systemic arterial hypertension (SAH) in the European Sleep Apnea Database cohort. METHODS: In a multicenter sample of 4,732 participants, we analyzed the risk of mild OSA (subclassified into 2 groups: mild(AHI 5-<11/h) (apnea-hypopnea index [AHI], 5 to <11 events/h) and mild(AHI 11-<15/h) (AHI, ≥11 to <15 events/h) compared with nonapneic snorers for prevalent SAH after adjustment for relevant confounding factors including sex, age, smoking, obesity, daytime sleepiness, dyslipidemia, chronic obstructive pulmona…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyEuropean Sleep Apnea Database Mild obstructive sleep apnea Systemic arterial hypertensionPolysomnographyDisorders of Excessive SomnolenceSettore MED/10 - Malattie Dell'Apparato RespiratorioHypertension risk03 medical and health sciences0302 clinical medicinestomatognathic systemRisk FactorsInternal medicinesystemic arterial hypertensionmedicineHumansEuropean Sleep Apnea DatabaseSleep Apnea ObstructiveSystemic arterial hypertensionbusiness.industrymedicine.diseaseScientific InvestigationsClinical neurologyrespiratory tract diseasesnervous system diseasesObstructive sleep apneamild obstructive sleep apneaDiabetes Mellitus Type 2NeurologyHypertensionNeurology (clinical)Human medicinebusiness030217 neurology & neurosurgery
researchProduct